Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05213195 | NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | unknown | Phase 1 | 38 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06253949 | Compare Outcomes After High and Low Ligation of Inferior Mesenteric Artery in Colorectal Cancer | unknown | N/A | 50 | Sohag UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06254300 |
| Online Exercise Program During Perioperative Treatment in Adults With Gastric Cancer(On4Cancer) |
| unknown |
| N/A |
| 40 |
| University of MaiaOTHER |
| 1 |
| Feb 12, 2024 |
| clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06074029 | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05173298 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab(HCC) | unknown | — | 100 | CHA UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05226221 | Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality(GESEMM) | unknown | — | 200 | Campus Bio-Medico UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05400408 | Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study(Cancer) | unknown | N/A | 250 | Scentech Medical Technologies LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05663788 | Web-based Learning Module on Optical Diagnosis of Early Colorectal Cancer(LODIP) | unknown | N/A | 166 | Althaia Xarxa Assistencial Universitària de ManresaOTHER | 4 | Feb 7, 2024 | clinicaltrials |
| NCT05980689 | Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06247293 | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy | unknown | — | 100 | Zhujiang HospitalOTHER | 0 | Feb 7, 2024 | clinicaltrials |
| NCT02556762 | Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer(SUMC-EC-002) | unknown | Phase 3 | 202 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05933980 | Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer(REGOTORICOX) | unknown | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06031818 | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction | unknown | — | 80 | Maastricht UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244446 | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | unknown | — | 40 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT00565708 | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers(ASCOLT) | unknown | Phase 3 | 1,587 | National Cancer Centre, SingaporeOTHER | 10 | Feb 2, 2024 | clinicaltrials |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | unknown | Phase 2 / Phase 3 | 1,194 | Alliance for Clinical Trials in OncologyOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT04161287 | Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE | unknown | — | 330 | Beijing 302 HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03799939 | Chimney Trial of Parastomal Hernia Prevention | unknown | N/A | 141 | University of OuluOTHER | 2 | Feb 1, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05291156 | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | unknown | Phase 2 | 173 | University of Campania Luigi VanvitelliOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06232538 | UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up | unknown | — | 1 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06236386 | Virtual Reality During Colonoscopy Procedures(VR) | unknown | N/A | 120 | University of Puerto RicoOTHER | 0 | Feb 1, 2024 | clinicaltrials |
| NCT03503630 | Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma | unknown | Phase 2 | 44 | Ali ShamseddineOTHER | 2 | Jan 31, 2024 | clinicaltrials |
| NCT04682847 | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | unknown | — | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233994 | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 30 | Changsha Taihe HospitalOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06235164 | The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer | unknown | — | 585 | Fujian Medical UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06223230 | Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors | unknown | N/A | 316 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06231017 | Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06231524 | Development and Validation of a PSN-AI Prediction Model(PSN-AI) | unknown | — | 50 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06227325 | Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression | unknown | Phase 2 | 27 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03872908 | Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies(ELEGANT) | unknown | — | 177 | Centre Leon BerardOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04883970 | CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors | unknown | N/A | 15 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06224738 | Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases | unknown | Early Phase 1 | 9 | First People's Hospital of HangzhouOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05737563 | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC(Escape) | unknown | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06010901 | A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | unknown | Phase 1 | 75 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06169410 | Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer | unknown | Phase 4 | 140 | Yang Jianjun, PhDOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218108 | Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal Adenocarcinoma(TAUTEM-pT1) | unknown | — | 317 | Corporacion Parc TauliOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06219395 | Capsule Endoscopy in Iron Deficiency Anaemia(WCE-IDA) | unknown | — | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Feb 12, 2024source: clinicaltrials